down arrow

ERIS Lifescience

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE406M01024
  • NSEID: ERIS
  • BSEID: 540596
INR
1,361.10
21.1 (1.57%)
BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 1.29 lacs

Click here to access the older version
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1,324.201,386.00

52 Week

815.501,593.00
Valuation
Technical
Day's Volume

CASH

1.29 lacs (69.58%) Volume

Shareholding (Dec 2024)

FII

8.35%

Held by 134 FIIs

DII

18.06%

Held by 23 DIIs

Promoter

54.86%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Dashboard
1

High Management Efficiency with a high ROCE of 19.25%

 
2

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.88 times

 
3

Poor long term growth as Operating profit has grown by an annual rate 15.22% of over the last 5 years

 
4

Flat results in Dec 24

5

Stock is technically in a Bullish range

6

With ROCE of 11.1, it has a Expensive valuation with a 3.9 Enterprise value to Capital Employed

7

High Institutional Holdings at 26.42%

8

Market Beating performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Pharmaceuticals & Drugs

stock-summary
Market cap

INR 18,533 Cr (Mid Cap)

stock-summary
P/E

55.00

stock-summary
Industry P/E

33

stock-summary
Dividend Yield

0.55%

stock-summary
Debt Equity

0.90

stock-summary
Return on Equity

12.57%

stock-summary
Price to Book

6.58

Revenue and Profits (1 Year):
Net Sales:
727 Cr
(Quarterly Results - Dec 2024)
Net Profit:
84 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0.55%)
TimePeriod
Price Return
Dividend Return
Total Return
6 Months
-1.8%
0.58%
-1.22%
1 Year
61.27%
0.83%
62.1%
2 Years
131.05%
1.17%
132.22%
3 Years
89.21%
2.22%
91.43%
4 Years
124.62%
2.91%
127.53%
5 Years
224.26%
5.35%
229.61%

Latest dividend: 7.35 per share ex-dividend date: Feb-13-2025

Risk Adjusted Returns v/s Sensex stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
21.51%
EBIT Growth (5y)
15.22%
EBIT to Interest (avg)
77.06
Debt to EBITDA (avg)
1.12
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.64
Tax Ratio
19.42%
Dividend Payout Ratio
0
Pledged Shares
18.51%
Institutional Holding
26.42%
ROCE (avg)
19.87%
ROE (avg)
18.53%
Valuation key factors
Factor
Value
P/E Ratio
55
Industry P/E
33
Price to Book Value
6.58
EV to EBIT
33.36
EV to EBITDA
22.71
EV to Capital Employed
3.94
EV to Sales
7.57
PEG Ratio
NA
Dividend Yield
0.55%
ROCE (Latest)
11.06%
ROE (Latest)
12.57%
Tecnicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

18.51

Mutual Funds

Held by 20 Schemes (16.52%)

FIIs

Held by 134 FIIs (8.35%)

Promoter with highest holding

Amit Indubhusan Bakshi (42.85%)

Highest Public shareholder

Lilac Investments Limited (8.79%)

Individual Investors Holdings

9.29%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2024 is 49.59% vs 14.89% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2024 is -18.60% vs 0.86% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "727.45",
          "val2": "486.30",
          "chgp": "49.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "250.31",
          "val2": "175.51",
          "chgp": "42.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "57.17",
          "val2": "18.12",
          "chgp": "215.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "83.63",
          "val2": "102.74",
          "chgp": "-18.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "34.66%",
          "val2": "36.30%",
          "chgp": "-1.64%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2024 is 50.31% vs 13.13% in Sep 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2024 is -19.94% vs 1.59% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,460.89",
          "val2": "971.92",
          "chgp": "50.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "514.50",
          "val2": "350.89",
          "chgp": "46.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "119.84",
          "val2": "33.65",
          "chgp": "256.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "174.77",
          "val2": "218.29",
          "chgp": "-19.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "35.37%",
          "val2": "36.53%",
          "chgp": "-1.16%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 50.07% vs 13.71% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is -19.51% vs 1.35% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,188.34",
          "val2": "1,458.22",
          "chgp": "50.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "764.81",
          "val2": "526.40",
          "chgp": "45.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "177.01",
          "val2": "51.77",
          "chgp": "241.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "258.40",
          "val2": "321.03",
          "chgp": "-19.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "34.95%",
          "val2": "36.10%",
          "chgp": "-1.15%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2024 is 19.23% vs 25.10% in Mar 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2024 is 2.57% vs -5.90% in Mar 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'24",
        "Mar'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,009.15",
          "val2": "1,685.15",
          "chgp": "19.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "674.83",
          "val2": "536.75",
          "chgp": "25.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "84.80",
          "val2": "26.17",
          "chgp": "224.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "391.98",
          "val2": "382.16",
          "chgp": "2.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "33.89%",
          "val2": "32.30%",
          "chgp": "1.59%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Dec'24 - YoYstock-summary
Dec'24
Dec'23
Change(%)
Net Sales
727.45
486.30
49.59%
Operating Profit (PBDIT) excl Other Income
250.31
175.51
42.62%
Interest
57.17
18.12
215.51%
Exceptional Items
0.00
0.00
Consolidate Net Profit
83.63
102.74
-18.60%
Operating Profit Margin (Excl OI)
34.66%
36.30%
-1.64%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2024 is 49.59% vs 14.89% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2024 is -18.60% vs 0.86% in Dec 2023

All Quarterly Resultsstock-summary
Half Yearly Results Snapshot (Consolidated) - Sep'24stock-summary
Sep'24
Sep'23
Change(%)
Net Sales
1,460.89
971.92
50.31%
Operating Profit (PBDIT) excl Other Income
514.50
350.89
46.63%
Interest
119.84
33.65
256.14%
Exceptional Items
0.00
0.00
Consolidate Net Profit
174.77
218.29
-19.94%
Operating Profit Margin (Excl OI)
35.37%
36.53%
-1.16%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

Growth in half year ended Sep 2024 is 50.31% vs 13.13% in Sep 2023

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2024 is -19.94% vs 1.59% in Sep 2023

All Half Yearly Resultsstock-summary
Nine Monthly Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
2,188.34
1,458.22
50.07%
Operating Profit (PBDIT) excl Other Income
764.81
526.40
45.29%
Interest
177.01
51.77
241.92%
Exceptional Items
0.00
0.00
Consolidate Net Profit
258.40
321.03
-19.51%
Operating Profit Margin (Excl OI)
34.95%
36.10%
-1.15%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is 50.07% vs 13.71% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2024 is -19.51% vs 1.35% in Dec 2023

All Nine Monthly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Mar'24stock-summary
Mar'24
Mar'23
Change(%)
Net Sales
2,009.15
1,685.15
19.23%
Operating Profit (PBDIT) excl Other Income
674.83
536.75
25.73%
Interest
84.80
26.17
224.04%
Exceptional Items
0.00
0.00
Consolidate Net Profit
391.98
382.16
2.57%
Operating Profit Margin (Excl OI)
33.89%
32.30%
1.59%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2024 is 19.23% vs 25.10% in Mar 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2024 is 2.57% vs -5.90% in Mar 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About ERIS Lifesciences Ltd stock-summary
stock-summary
ERIS Lifesciences Ltd
Mid Cap
Pharmaceuticals & Drugs
Eris Lifesciences Limited was incorporated on January 25, 2007. Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007. Further, the Company was converted into a Public Limited cCompany and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017. The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products.
Company Coordinates stock-summary
Company Details
8th Floor Commerce House -IV, Prahladnagar 100 FT Road Ahmedabad Gujarat : 380015
stock-summary
Tel: 91-79-30451000
stock-summary
http://www.eris.co.in
stock-summary
complianceofficer@erislifesciences.
Registrar Details
Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."